Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Fusion

Fusion

CIViC ID: 2681 · Gene: RCSD1::ABL1

Variant Summary

Also known as: RCSD1-ABL1
HGVS: —
Variant Type(s): transcript_fusion
Evidence Items: 13

Evidence Level Distribution

Level C: 12Level D: 1

Evidence Items

Showing CIViC evidence rows where gene = RCSD1::ABL1 and variant = Fusion.

Level	Type	Direction	Significance	Disease	Drugs	Rating
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Imatinib	3
D	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Dasatinib	3
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Imatinib	3
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Dasatinib	3
C	Predictive	Supports	Reduced Sensitivity	B-lymphoblastic Leukemia/lymphoma	Dasatinib	3
C	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma		3
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Dasatinib	3
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Ponatinib	3
C	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like		2
C	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like		2
C	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma		2
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma	Dasatinib	2
C	Predictive	Supports	Sensitivity/Response	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like	Tyrosine Kinase Inhibitor	2